Big effect
Inhaled Clostridium butyricum slashed pneumonia risk from 46% to 2% in a 310-person trial — but the delivery method (nebulization) is far from everyday use.
This is a striking early signal for a novel probiotic delivery route, but it comes from a single study — so treat the size of the effect as promising, not settled.
Hospital patients who inhaled a live probiotic via oxygen-driven nebulizer were 23 times less likely to develop drug-resistant bacterial pneumonia than those who got standard care. The same group also showed faster clearance of airway secretions and lower inflammation markers — but because the probiotic was inhaled rather than swallowed, these results don't apply to the capsules you can buy online.
Where this fits in the evidence
This is among the first studies we've indexed on Clostridium butyricum for Reduced Incidence of Bacterial Pneumonia — treat it as an early signal until more research accumulates.
The study
Oxygen-driven nebulization of Clostridium butyricum prevents drug-resistant bacterial pneumonia.
- Randomized Controlled Trial (RCT)
- n = 310
- 2026-01-24
- Applied microbiology and biotechnology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.